| Business Type(s) |
| Primary/Secondary | Business Type | Details |
| Primary
| *Cardiovascular Research and Development
| In the process of developing a cardiovascular product called MC-1, for treatment of a variety of specific disorders including heart attacks and high blood pressure. The company states that it is in the process of discovering new compounds that may treat such disorders.
|
|
| *TEMPORARILY UNCLASSIFIED BUSINESS TYPE
| (not available)
|
|
|
| Securities |
| Symbol | Security Name | Market | Status |
| *MPH | *Medicure Inc. | TSX Venture | DELIST |
| *MPH.A | *Medicure Inc. cl A | TSX Venture | DELIST |
| *MPH.WT | *Medicure Inc. wt 22De03 | TSX Venture | DELIST |
| *MPH | *Medicure Inc. | WSE | DELIST |
| *MPH.A | *Medicure Inc. cl A | WSE | DELIST |
| *LCC | *Lariat Capital Inc. | TSX Venture | DELIST |
| *LCC | *Lariat Capital Inc. | ASE | DELIST |
|
|
| Name History | From | To |
| *Medicure Inc. | 7/Jan/2000 | 14/Mar/2002 |
| *Lariat Capital Inc. | 14/Jul/1997 | 6/Jan/2000 |
|
|
| Company Facts Reconciliation |
| Subject | Date Returned |
| Spring 2001 CFR | 5/Jun/2001 |
|
|
|
|
